REG - Futura Medical PLC - Director/PDMR Dealing

Futura MedicalAnnouncement

17/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240117:nRSQ8963Za&default-theme=true

RNS Number : 8963Z  Futura Medical PLC  17 January 2024

 

17 January 2024

 Futura Medical plc

("Futura" or the "Company")

Director/PDMR Dealing

Futura Medical plc (AIM: FUM), the pharmaceutical company developing
innovative sexual health products, today announces that it has been notified
that James Barder and his spouse, Charlotte Barder have gifted in aggregate
20,000 Ordinary Shares to a family member as part of inheritance and tax
planning.

Following this transaction James Barder's interests in Ordinary Shares is
1,420,972 Ordinary Shares, representing approximately 0.5% of the Company's
issued share capital.

 

ENDS

 

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Elena Bates

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing
innovative products based on its proprietary, transdermal
DermaSys® technology.

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED")
has a unique evaporative mode of action and is clinically proven as an
effective topical treatment for adult men with ED, with a key claim of
"Helps you get an erection within 10 minutes". Eroxon® is available Over the
Counter ("OTC") without a doctor's prescription. www.eroxon.com
(http://www.eroxon.com/) .

MED3000 is being manufactured and commercialised under the brand name Eroxon®
and has been granted marketing authorisation by the FDA in the US, CE marked
in Europe, UKCA marked in the UK and is gaining regulatory approval in a
growing number of countries across the world. Futura has commercial agreements
with Haleon for the US market and Cooper Consumer Health for Europe.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         James Barder

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    1.     Transfer to PCA

                                                                   2.     Transfer to family member
 c)   Price(s) and volume(s)

  Price(s)  Volume(s)

                                                                   1.  nil       10,000
                                                                   2.  nil       10,000
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      17 January 2024

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

17 January 2024

f)

 

Place of the transaction

 

Outside of trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Charlotte Barder

 2    Reason for the notification
 a)   Position/status                                              PCA of James Barder

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    1.     Receipt of shares from PCA

                                                                   2.     Transfer to family member
 c)   Price(s) and volume(s)

  Price(s)  Volume(s)

                                                                   1.  nil       10,000
                                                                   2.  nil       10,000
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      17 January 2024

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

17 January 2024

f)

 

Place of the transaction

 

Outside of trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAKFKFSFLEFA